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Abstract In this review, we report on electrical modali-
ties, which do not fit the definition of pacemaker, but
increase cardiac performance either by direct application to
the heart (e.g., post-extrasystolic potentiation or non-
excitatory stimulation) or indirectly through activation of
the nervous system (e.g., vagal or sympathetic activation).
The physiological background of the possible mechanisms
of these electrical modalities and their potential application
to treat heart failure are discussed.
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Introduction
The use of electrical therapy for cardiac rhythm distur-
bances is acknowledged for decades, with a primary
emphasis on pacing for rate support (e.g., atrioventricular
block or sinus node disease), cardiac resynchronization
therapy (CRT), and implantable cardioverter-defibrillators
(ICD). This review will focus on less well-known electrical
therapies for treatment of heart failure (HF) or for pre-
vention of the progression into heart failure. These
therapies are either in their infancy or not yet approved for
the treatment of HF. Some discussed therapies might be
more beneficial for HF secondary to prior infarction, while
other therapies might be more applicable to HF linked to
other pathologies such as hypertension or diabetes.
A decrease in contractility is undoubtedly a major
contributing factor in the pathophysiology of a significant
portion of the patients with heart failure. A reasonable
therapeutic goal in these patients would then be to increase
cardiac contractility either acutely or long term. The
chronic use of inotropic drugs to treat chronic HF has fallen
out of favor with the medical community because of the
increased mortality seen with these drugs in large clinical
trials [1, 2]. The use of novel stimulation therapies, pre-
sented in this review, may offer alternative ways of
improving atrial and/or ventricular function. The discussed
therapies are divided into electrical stimulation directly on
the heart or neural stimulation that affects the heart, such as
vagal nerve or spinal cord stimulation. For an overview of
the different electrical therapies addressed in this chapter
and to know when they are applied within the cardiac
cycle, see Fig. 1.
Electrical stimulation on the heart
Post-extrasystolic potentiation (PESP)
Post-extrasystolic potentiation (PESP) is an intrinsic
property of mammalian cardiac muscle, whereby closely
spaced depolarizations increase the contractility of the
following beat (Fig. 2) [3]. The degree of potentiation
produced by an extrasystole depends upon the extrasystolic
coupling interval, with increasing potentiation at shorter
coupling intervals. In the intact heart, there may be
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increased filling after the premature beat, increasing con-
tractile force due to the Frank-Starling effect, but studies in
isovolumic hearts and isolated muscle have shown that
increased filling has a minor contribution on the magnitude
of the effect of PESP [4].
The mechanism responsible for PESP is thought to
involve alterations in the uptake and release of Ca2? from
the sarcoplasmic reticulum (SR) [5]. The amount of Ca2?
delivered across the cell membrane into the cell during the
depolarization, and the uptake by the SR is relatively
normal during the extrasystole. But the extrasystole occurs
before the SR has fully recovered and results in reduced SR
Ca2? release, which leads to reduced cytosolic Ca2? con-
centration and little developed force (S2 of C in Fig. 2). A
relatively normal uptake of Ca2? occurs during relaxation,
but because a less than normal amount of Ca2? was
released from the SR during the extrasystole, the SR is now
loaded with more Ca2? than normal. The result is that on
the following beat, the SR releases more Ca2? than normal,
resulting in a stronger contraction (S3 of C in Fig. 2). The
extrasystole generally does not develop enough pressure to
eject blood into the aorta.
PESP can be delivered in either a coupled pacing mode,
where premature stimuli are delivered after every intrinsic
ventricular depolarization, or a paired pacing mode, where
premature stimuli are delivered after every ventricular
pace. An enhancement to coupled pacing is to deliver it in a
dual-chamber mode, where both the atrium and ventricles
are prematurely depolarized. Dual-chamber coupled pacing
(DCCP) may improve hemodynamics over coupled pacing
levels by also enhancing atrial transport function through
atrial PESP.
Clinical applications
There was intense interest in the acute effects of paired/
coupled pacing on cardiac performance in both animals and
patients from approximately 1960 to 1970 [6–9]. A canine
study in 1966 showed that paired pacing has little effect on
baseline cardiac output or mean arterial blood pressure, but
when ventricular contractility is depressed by a high dose
of pentobarbital, paired pacing increases cardiac output and
blood pressure [8]. External pacemakers were developed in
the 1960s that performed both coupled and paired ven-
tricular pacing, and the first published record of coupled
pacing in a human subject was performed by Eugene
Braunwald [6] in the cardiac catheter lab in 1964. An early
clinical study in 7 patients with cardiogenic shock in the
presence of acute myocardial infarction showed that cou-
pled pacing dramatically improved cardiac function with a
clearing of the shock and/or failure in 4 patients [10]. In
that series, coupled pacing did not provoke ventricular
arrhythmias, whereas paired pacing caused repetitive ven-
tricular responses in 2/3 cases in which it was applied.
Despite the early enthusiasm in paired/coupled pacing as a
means of improving contractility, the interest in this type of
AP
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Fig. 1 Overview of the timing
of the different electrical
therapies. Note PESP can also
be given after the refractory
period of the atrium. This,
however, is not depicted in the
figure. In some cases, SS was
also administered exclusively
during the refractory period of
the ventricles (see text for
details). VS vagal stimulation,
SCS spinal cord stimulation, SS
sympathetic stimulation
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pacing waned in the 1970s for unknown reasons. Concerns
of pro-arrhythmia and increased metabolic demand were
emphasized in several of the early publications [7, 9].
We have recently evaluated the effects of coupled
pacing in patients with heart failure [11, 12]. In 16 subjects
with NYHA class II or III symptoms and an ejection
fraction (EF) \35%, DCCP was acutely applied. The
ventricular-coupled paces were delivered 10 ms after the
individually measured effective refractory period
(ERP = 321 ± 41 ms), and atrial rate support at 45 bpm
(excluding the intentional premature beats) was provided
during DCCP, if necessary. Compared to normal sinus
rhythm (NSR), DCCP increased LV dP/dt max., a surro-
gate for contractility, by 33 ± 15% and arterial pulse
pressure by 35 ± 24% (see Fig. 3). There were no signif-
icant changes in mean arterial pressure, mean pulmonary
artery pressure, cardiac output, or mixed venous O2 satu-
ration. DCCP as delivered in this study resulted in a
decrease in heart rate (29 ± 12%). The increase in LV dP/
dt max was substantially less than the 72% increase in LV
dP/dt max than reported in a previous study by Geschwind
et al. that evaluated the hemodynamic effects of 10 min of
RV coupled pacing in 30 patients with normal LV function
(EF [ 45%) [13]. The explanation for the lower-than-
expected coupled pacing induced increase in contractility
in our study is not clear. It is possible that the chronic use
of drugs such as beta blockers or angiotensin-converting
enzyme inhibitors altered the response of HF patients to
coupled pacing. A second possibility is that the increase in
contractility in HF patients may have been attenuated due
to sarcoplasmic reticulum (SR) dysfunction. Since PESP
relies on the function of the SR, it may well be that the SR
dysfunction in HF attenuates the ability of coupled pacing
to increase contractility. An additional observation in the
Geshwind study was that during coupled pacing, arterial
and coronary plasma norepinephrine levels increased,
suggesting sympathetic nervous system activation. This
may have been due to a decrease in mean arterial pressure
of 13% in that study.
Studies have shown that ventricular coupled pacing may
provide effective rate control and improve hemodynamics
during rapidly conducted atrial fibrillation [14] or ventric-
ular tachycardia [15]. However, the benefit is likely due to
a reduction in ventricular rate rather than an improvement
in the intrinsic contractility.
Non-excitatory stimulation (NES)
Electrical stimulation of the myocardium during the
refractory period (see Fig. 1) can also result in an increase
in contractility. The increase in contractility is a function of
the amplitude of the stimulation and the location of the
stimulating electrodes [16–18]. The stimulation is not
conducting—it does not depolarize the myocardium.
Therefore, we will refer to this type of stimulation as non-
excitatory stimulation or NES. Different trains of pulses
can be applied. The two modes described in this review are
depicted in Fig. 4 and are referred to as monophasic or
biphasic trains.
Preclinical results
Early research in NES was focused on understanding how
this stimulation interacted with the heart and the autonomic
nervous system. In the 1960s and 1970s, there were various
studies conducted, which demonstrated the effects of
electrical stimulation on both the parasympathetic and
sympathetic innervation on different structures of the heart
(sinoatrial node, atrioventricular node [19], ventricles
[20]). In 1966, Blinks et al. [16] showed that field stimu-
lation of isolated heart muscle increased the release of
autonomic transmitters in a stimulus-strength-dependent
manner. These data support the idea that the inotropic
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Fig. 2 Example of the concept of post-extrasystolic potentiation. The
coupling interval represents the time difference between the first and
second depolarization and is ECG-based. The shorter the coupling
interval, the bigger the contractility increase of the S3, but the smaller
the amplitude of the S2. The drop in mechanical heart rate is similar.
The y-axis displays normalized pressure while the x-axis displays
time
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response to NES is mediated by the sympathetic nervous
system.
In contrast, in isolated tissue and papillary muscle, the
dominant mechanism for increased force generation during
NES appears to be field stimulation of the cardiac cells,
which alters Ca2? dynamics. In isolated papillary muscles,
both cathodic and anodic NES stimulation have been
applied [21]. During cathodic stimulation (negative
amplitude), action potential duration and developed force
(-17 ± 3%) decreased, while anodic stimulation (positive
amplitude) increased both (developed force by 68 ± 15%).
These opposite effects of anodic and cathodic NES have
been attributed to differential effects on intracellular cal-
cium availability during the contraction, either through
altered SR-calcium release or changed cytosolic calcium
extrusion [21]. Additional tests of the anodic stimulation in
the presence of Ca2? channel blockers, b-adrenergic
receptor blocker, and ryanodine supported the hypothesis
that monophasic stimulation impacts Ca2? dynamics, in
particular by loading the sarcoplasmic reticulum with more
Ca2? to be released on the subsequent beat, similar to
PESP (see above). Stimulation of (sympathetic) nerves as a
mechanism of changing contractility during anodic or
cathodic stimulation was excluded on basis of experiments
using propranolol or timing between the observed effect
and start of stimulation [21]. However, full beta blockade
was not demonstrated, and high energy stimulation of
papillary muscles in vitro may, in fact, stimulate the nerves
[22].
When studied in intact hearts, the data on the mecha-
nism of NES are mixed. During application of NES in
anesthetized, healthy canines contractility increased in the
region near the stimulating electrodes and norepinephrine
levels increased [17]. The increase in contractility was
abolished by complete beta blockade and when the heart
was denervated. In our lab, we have reproduced these
Fig. 3 Actual human data
displaying the PESP response
[own observations]. The onset
of dual chamber coupled pacing
in a representative human
experiment. The analog records
are arranged in the following
order: atrial electrogram
(AEGM), ventricular
electrogram (VEGM), ECG
(lead II), aortic blood pressure
(ARTP), and left ventricular
pressure (LVP). The large
stimulus artifacts in the atrial
and ventricular electrograms
show the timing of the atrial and
ventricular paced events.
Coupled pacing is depicted on
the right. It clearly displays the
fusion of the intrinsic beat and
the extrasystole and the
relatively large extrasystole
amplitude (see text for details)
Fig. 4 Waveforms used for
NES. The differences between
the waveforms applied for non-
excitatory stimulus.
a monophasic train and
b biphasic train
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results showing an increase in LV dP/dt max of
14.1 ± 8.2% during NES stimulation with leads placed in
the RV apex and anterior-interventricular vein that was
significantly decreased to 1.4 ± 1.0% by beta blockade
with metoprolol (1 mg/kg IV) (see Fig. 5). In a separate
study in healthy dogs, we further demonstrated that cardiac
norepinephrine spillover increased fourfold during NES
suggesting sympathetic involvement (see Fig. 6). These
results are in contrast to a study done in isolated ferret
hearts by Mohri et al. [23]. In this study, NES (biphasic
square wave, ±20 mA) resulted in an increase in peak-free
intracellular calcium ([Ca2?]i) and increased LV pressure.
After the application of 1 mg/l of propranolol (a sympa-
thetic blocker), the increase in both [Ca2?]i and LV pres-
sure remained, albeit due to NES smaller than if no
propanolol was added before beta blockade.
In another dog study, Mohri et al. also demonstrated
that application of NES on the LV anterior wall in canines
increased contractility in the anterior region of the heart and
decreased contractility in the posterior region [18]. These
results were reversed when NES was applied in the
posterior region. However, the effects of NES on global
contractility, as measured by LV dP/dt max, were positive
during NES (23.3 ± 12%, 26.0 ± 9.3%, and 31.3 ± 12.5%
for anterior, posterior, and both respectively). Acute
improvements in global functional measures have also been
demonstrated in dogs with LV dysfunction (through serial
coronary micro-embolizations) using the biphasic
waveform after 10 min to 6 h of stimulation [24, 25] and
more recently in rabbits with heart failure due to myocardial
infarction [26].
We investigated the effect of electrode positioning on
the response to NES [27]. NES was delivered with uni-
polar, epicardial leads on three locations (proximal, mid,
and distal) along the left anterior descending (LAD), left
circumflex (LCX), and right coronary artery (RCA) acutely
in canines. The more proximal the stimulation site was, the
larger was the increase in LV dP/dt max, and was largest
during proximal LAD NES (14 ± 7%). NES at the RCA
sites had no effect on LV dP/dt max, but strongly enhanced
RV dP/dt max, indicating the localized effect of NES
application. The extent of increase in LV dP/dt max when
during LAD or LCX NES was accompanied by a similar
degree of impairment of LV relaxation (e.g., LV dP/dt min
decreased by 11 ± 7% during proximal LAD NES). Dur-
ing prolonged NES delivery (1 h), the contractility aug-
mentation significantly decreased from 11 ± 12% to
6 ± 4%. This was accompanied by a corresponding drop in
NA-release into the coronary sinus (Fig. 7). These data
support the link between the increase in LV dP/dt max and
the direct activation of the sympathetic nervous system.
NES has been applied chronically in HF dogs. NES was
applied intermittently (6 h/day) to the LV via two coil
electrodes in the great cardiac vein for 3 months [24]. The
animals receiving NES showed a significant decrease in
LVEDP and a significant increase in SV. However, there
was also an increase in LVEDV (continued remodeling)
and a lack of increase in LV dP/dt max. The non-treated
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Fig. 5 Effects of metoprolol on the increase of LV dP/dt max during
NES. Data from 7 anesthetized animals (4 dogs, 3 pigs). NES was
delivered through 1 RV lead and 1 LV lead as a biphasic square wave
(–8 V) 40 ms after the sensed ventricular event. Stimulation was
applied for 5 min with 5 min of normal sinus rhythm before and after
stimulation. The median of the last minute of stimulation was used to
measure LV dP/dt max. There was a significant reduction in response
to NES after the application of metoprolol with no significant change
in heart rate or blood pressure. Values plotted are mean ± standard
deviation
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Fig. 6 Coronary sinus catecholamine concentrations during NES.
NES was delivered with a monophasic pulse train. Stimulation was
applied continuously for 10 min. This was preceded by a 10-min
baseline period and followed by a 10-min recovery period. Coronary
sinus and arterial blood samples were withdrawn (10 ml) at the end of
each 10-min period and analyzed for epinephrine and nor-epinephrine
by radioimmunoassay. Coronary sinus epinephrine did not show a
significant change during NES
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dogs worsened in many of these measures, however. Later
studies showed changes in gene and protein expression
related to Ca2? dynamics. The treated animals demon-
strated significantly different levels of gene and protein
expression from the controls, and the changes were in the
direction of a non-diseased expression [28, 29]. In another
study in dogs with HF, 3 months of NES in dogs with HF
shifted protein expression of cytoskeletal proteins and
matrix metalloproteinases from pathological toward nor-
mal levels [30].
Clinical applications
The acute effects of NES have been evaluated in 18
patients with heart failure and a narrow QRS complex [31].
Two multipolar catheters were placed in the RV, and a LV-
pacing lead was placed in a coronary vein. NES was
delivered using various electrode configurations including
dual- RV site and LV-only NES. An increase in LV dP/dt
max greater than 5% was achieved in 7 (39%) patients, of
whom 4 had LV NES and 3 had dual-RV site NES. No
patient discomfort was observed during NES delivered via
the RV. Ten patients experienced chest discomfort during
NES delivered via the LV and required a reduction in
stimulation amplitude.
In addition to this acute data in human HF, biphasic
NES therapy has been studied in several other feasibility as
well as in chronic studies [31, 32]. Uncontrolled feasibility
studies have demonstrated the safety of the therapy [31],
and more recently, randomized controlled non-blinded
pivotal studies have been conducted in Europe (FIX-HF-4)
and in the United States (FIX-HF-5).
Evidence of remodeling and effects on global contrac-
tility due to NES have been reported in a non-controlled
unblinded feasibility study of 30 class II HF subjects [33].
LV size was measured using three-dimensional echocar-
diography. Contractile function was assessed using tissue
Doppler imaging. NES therapy was applied for 3 months in
all subjects. There was a significant decrease in LV ESV
and increase in EF compared to baseline. In addition, peak
systolic velocity was increased in all six basal LV seg-
ments, even those segments distal to the delivery electrode.
Global contractility improved also. There was an
improvement in NYHA functional class and 6-minute hall
walk as well. Although this study was not controlled or
blinded, these data support testing NES in a larger ran-
domized trial.
NES was also studied in a small group of patients
(N = 16) who did not respond to CRT [32]. Subjects were
followed an average of 147 ± 80 days, while several
complications such as lead dislocation and appropriate
defibrillation were observed, there also was an improve-
ment in NYHA class and ejection fraction. In addition, no
electrical interference between the ICD and the NES sys-
tem was observed.
FIX-HF-4 was a randomized single-blind, cross-over
study in which patients received 3 months of active therapy
and 3 months received no therapy [34]. Two leads were
implanted in the RV, and NES was applied intermittently
for a total of 7 h a day. The primary endpoints were peak
VO2 and the MNLWHF quality of life (QOL) question-
naire. Both of these measures improved similarly for the
control and therapy groups in the first 3 months of the
study. After the cross over, the group that went from ON to
OFF showed a worsening VO2 peak and QOL, while the
group that went from OFF to ON showed a very small
improvement in both measures. These data suggest a
moderate difference between the two groups by the end of
the study. In 11 patients, endomyocardial biopsies were
obtained at baseline and 3 and 6 months thereafter to test
the impact of NES signals on myocardial gene expression
[35]. The NES signals were delivered in random order of
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Fig. 7 Extended application of monophasic NES. The effect of
60 min of monophasic NES (3 pulses, 8 V, 1.5 ms/pulse; 40 ms after
the R wave via one epicardial patch electrode in 5 anesthetized dogs)
and 30 min recovery (REC) on normalized changes in LV dP/dt max
and the release of nor-adrenaline into the coronary sinus. Data of
contractility were normalized to the baseline measurements just
before the onset of stimulation. Values are presented as mean ±
SEM. During prolonged RPS delivery, the contractility augmentation
significantly decreased from 11 ± 16% to 6 ± 2%. This was
accompanied by a similar drop in NA-release into the coronary sinus
from 1.08 ± 0.38 to 0.47 ± 0.06 nmol/l (baseline 0.24 ± 0.07 nmol/
l). Therapy was delivered unipolar with one lead placed on the basal
anterior site (close to the LAD)
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ON for 3 months and OFF for 3 months. The NES signal
treatment reverses the cardiac maladaptive fetal gene pro-
gram and normalizes expression of key sarcoplasmic
reticulum Ca2? cycling and stretch response genes. These
changes may contribute to the clinical effects of NES.
In the FIX-HF-5 study, conducted in the United States,
patients were randomized to optimal medical therapy
(OMT) or OMT plus NES therapy and followed for
12 months [36]. The study was unblinded due to the con-
trol group not receiving an implant. Results have not yet
been published in a peer-reviewed journal, but were pre-
sented orally at the American College of Cardiology con-
ference in 2009 [37]. The study enrolled 428 NYHA class
III-IV subjects with EF B 35% and a narrow QRS [38].
NES was delivered intermittently for 5 h/day. The primary
efficacy endpoint of ventilatory anaerobic threshold (VAT)
was not met. However, secondary endpoints of VO2 peak,
quality of life, and NYHA class improved significantly.
Subgroup analysis suggested that the therapy may be best
suited to benefit NYHA III subjects with an EF C 25%, as
VAT increased significantly in this subgroup.
Given the data suggesting that the mechanism of effect
may be stimulation of local sympathetic nerves, there has
been concern about this therapy in systolic HF, in which
sympatho-mimetic drugs have been proven to be detri-
mental [2]. It is possible, however, that NES might avoid
the issues seen with inotropic drugs because the stimulation
is localized to the myocardium and is delivered intermit-
tently. NES does not appear to generate a systemic sym-
pathetic response. In addition, since some inotropic drugs
have been shown to increase myocardial oxygen con-
sumption, this also is a concern for NES. In a small study
of both dogs and HF patients, however, up to 30 min of
NES was shown to have no effect on myocardial oxygen
consumption [39].
While the results of these studies suggest that there may
be benefit to the NES therapy, the strong beneficial effect
in the control group and the lack of meeting the primary
endpoint in the pivotal suggest that additional studies are
needed to find the optimal patient population for this
therapy.
Infarct borderzone pacing
Left ventricular remodeling is a well-known complication
after an acute myocardial infarction, which can progress
into heart failure. Peri-infarct (borderzone) pacing has
recently been proposed as a therapy for the prevention of
adverse remodeling [40]. This peri-infarct borderzone
pacing is intended to deliberately induce dyssynchrony,
which is in contrast to CRT, which pre-excites the
endogenously late activating (lateral) segments of the left
ventricle, which results in a more synchronous contraction
of the ventricle. Remodeling initiated by increases in
(systolic) wall stress in the infarcted area can be counter-
acted by electrical pre-excitation and subsequent unloading
of that region. The hypothesis is based upon previous work
in normal animals that showed that pacing-induced pre-
excitation decreased strain and myocardial work at the
pacing site and increasing strain distal to it [41]. This
concept of regional unloading is in line with benefits of
global left ventricular unloading, such as by cardiac assist
devices or vasodilators [42–44].
Shuros et al. investigated the optimal pacing site and
optimal AV-delay to deliver borderzone pacing in acute
experiments in pigs by local strain and stroke work
parameters. An AV interval of 50% of the intrinsic PR
interval was shown to acutely reduce the strain in the
ischemic borderzone without significantly impeding car-
diac output [40]. These pigs were then chronically stimu-
lated and followed for 2 months. Chronic application of
pre-excitation pacing attenuated adverse remodeling over
time as evidenced by the morphometric data on LV and LA
size. Soon after, Saba et al. [45], using small animals with a
posterolateral infarct, showed prevention of adverse elec-
trical and mechanical cardiac remodeling with BiV pacing
compared with right ventricular pacing or no pacing after
MI.
More insight into the cellular mechanism of borderzone
pacing may be provided by a recent study in which regional
early LV activation, as in pre-excitation, was also able to
change matrix metalloproteinase (MMP)-activity [46, 47].
MMPs are a family of matrix proteases implicated in
adverse LV remodeling through matrix remodeling [48].
Other studies have shown that localized high frequency
(non-capturing) stimulation within the infarct prevented the
thinning of this area and attenuated left ventricular dilata-
tion [49], being associated with beneficial decreased
changes in matrix metalloproteinase (MMP) activity as
well. This would corroborate the involvement of MMPs in
electrical borderzone stimulation. Also, electrical stimula-
tion of its own accord can induce beneficial gene and
protein expression [50].
Clinical applications
Infarct borderzone pacing is just beginning to be explored
in humans. In a small pilot clinical study, patients with
reduced EF secondary to myocardial infarction were ran-
domized to either biventricular borderzone (BiV) pacing
with ICD or ICD alone within 30–45 after MI [51]. After
12 months, LV size was unchanged in the BiV pacing
group while it increased in the ICD-only group. These
positive results prompted a larger study, called the MEND-
MI study [52]. This study evaluated biventricular bor-
derzone pacing in a narrowly defined patient population
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with the borderzone pacing therapy delivered within
14 days after myocardial infarction. The recently published
results show that the primary endpoint (change in LV end-
diastolic volume after 12 months therapy) was not met [53]
(study identifier: NCT00605631). Possible explanations for
the discrepancy between this trial and the earlier results
might be the relatively low LV remodeling or an ineffica-
cious therapy delivery. The therapy is a pathophysiologi-
cally based approach and needs further investigation.
Electrical stimulation outside the heart
In the previous paragraphs, we have discussed the appli-
cation of electrical stimulation on the heart, which has the
advantage of avoiding possible adverse side-effects as
regularly encountered with pharmacological therapies. The
therapies discussed below are applied outside the heart and
usually are applied continuously throughout the cardiac
cycle (see Fig. 1). Their benefit may be that the stimulation
is affecting a much more integrated system. Studies of
these therapies clearly show cardiac benefit, but in most
cases, the exact mechanism is unknown. This is likely due
to multi-organ and central nervous system pathways.
Vagal nerve stimulation
There has been extensive research demonstrating that acute
vagus nerve stimulation results in a decrease in various
measures of ventricular function including contractility.
Lewis et al. showed that in the human and pig heart,
stimulation of the left vagus nerve can profoundly decrease
contractility of the left ventricular myocardium, indepen-
dent of its braducardic effect [54]. This decrease in ven-
tricular contractility during vagal stimulation (VNS)
appears to be mediated by the parasympathetic ganglia
located in the cranial medial ventricular fat pad [55, 56].
However, at low sympathetic tone, the negative inotropic
effect of vagal stimulation is attributable primarily to its
negative chronotropic effect [57]. This suggests that the
effect of VNS on contractility is mediated via an interac-
tion with the sympathetic system.
It may seem counterintuitive that a reduction in con-
tractility by VNS may be beneficial to patients with heart
failure. However, several pre-clinical studies have shown
benefit in chronic vagus nerve stimulation in models of
systolic heart failure [58]. Recently, Zhang et al. evaluated
VNS in a canine high-rate pacing-induced model of heart
failure. VNS at an intensity that reduced sinus rate by
approximately 20 bpm was delivered in the VNS group.
After 4 and 8 weeks, both left ventricular end-diastolic and
end-systolic volumes were lower, and left ventricular EF
was higher in the VNS group than in the control group [59].
Li et al. showed that VNS markedly improved the long-
term survival of chronic heart failure rats through the
prevention of pumping failure, remodeling, and increasing
contractility [60]. Very recently, the same group showed
that VNS applied immediately after MI attenuated LV
remodeling, which may be related to the decreased acute
inflammatory response or to the reduction in infarct size
induced by VNS [61], since the remodeling process
increases with a larger infarct.
Clinical applications
A phase I clinical study has been conducted in Europe
demonstrating the safety and feasibility of chronic vagus
nerve stimulation in systolic heart failure patients. The
system, CardioFit (BioControl Medical), is an implantable
device and lead delivering pulses synchronous with the
cardiac cycle to the right cervical vagus nerve. A cohort of
30 patients has been reported on. After 3 months of VNS,
the subjects had significant improvements in NYHA class,
Minnesota quality of life, QOL, (from 52 ± 14 to
31 ± 18), left ventricular end-systolic volume (from
208 ± 71 to 190 ± 83 ml), and a favorable trend toward
reduction in end-diastolic volume [62]. After 6 months of
VNS, EF, 6-min hall walk, and QOL had significantly
improved. These encouraging results need to be confirmed
in a randomized controlled trial.
Sympathetic stimulation
Sympathetic–parasympathetic interaction plays a major
role in the evolution and outcome of HF. Numerous sym-
patho-mimetic drug studies have shown acute beneficial
but chronic adverse effects. The major concerns with using
these drugs are the increased mortality associated with their
use, in addition to an increase in cardiac oxygen con-
sumption and side-effects [1]. Sympatho-mimetic electrical
therapies may be able to circumvent the adverse profile of
sympatho-mimetic drugs by being more selective to sym-
pathetic nerves on the heart and by their intermittent
nature.
Selective stimulation of the cardiac sympathetic nerves
by transvascular stimulation of the heart has been shown
[63, 64]. Cardiac sympathetic nerves course within neural
sleeves along the subclavian artery. Because of this prox-
imity, transvascular sympathetic nerve stimulation was
attempted with electrode catheters inside the subclavian
artery. Right as well as left subclavian sympathetic nerve
stimulation (20 Hz) during high-rate ventricular pacing
evoked a more than 100% increase of left ventricular
systolic pressure. In a separate study [64], sympathetic
neural structures inside the heart were identified that
selectively control left ventricular inotropy and could be
322 Heart Fail Rev (2011) 16:315–325
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accessed by transvenous catheter stimulation. High fre-
quency (200 Hz) stimulation was applied in the ventricular
absolute refractory period (50 ms long, 20 ms after the
R wave; resembling NES; see above) during pacing at
120 bpm. Stimulation generated a significant increase in
LV dP/dt max (*50%), LV peak pressure (*40%), car-
diac output (*25%), and the slope of the end-systolic
pressure–volume relationship (*35%), a load independent
measure of contractility. The effect was abolished by acute
beta blockade, indicating that the effect was likely due to
sympathetic nerve simulation. In addition, the transcardiac
norepinephrine gradient increased from 0.15 to 3.7 nmol/l
during stimulation.
For comparison, if the stellate ganglion was stimulated,
norepinephrine content rose 200 times in the coronary
artery when compared to baseline [65], which indicates the
relatively gentle and local nature of the above-mentioned
transvenous approach to sympathetic stimulation. How-
ever, due to the nature of the nerve stimulus (high fre-
quency and throughout the cardiac cycle), adverse events
like ventricular extra systoles and atrial or ventricular
arrhythmias are anticipated. Further studies are required to
show the safety and efficacy of this novel approach.
Spinal cord stimulation
Thoracic spinal cord stimulation (SCS) has been used to
treat angina pectoris and to affect cardiac autonomic bal-
ance. Although the precise mechanism is unknown, current
evidence suggests that spinal cord stimulation at the T1–T5
level decreases sympathetic tone to the heart [66, 67].
Rebalancing the autonomic nervous system may reduce the
systemic release of cathecholamines, reduce sympathetic
activation of the renin-angiotension system in the kidneys
and have an anti-arrhythmic effect [68]. In addition, spinal
cord stimulation might activate large afferent fibers;
GABAergic connections in the superficial dorsal horn may
suppress the processing of information in the spinothalamic
tract neurons [69] or via VR-1 containing sensory fibers
[70]. There are also effects of SCS seen in the vasculature
that could result in benefits in HF. For a full review on the
beneficial effects of SCS on the vasculature, see Wu et al.
[71].
Lopshire et al. [72] investigated the effects of long-term
SCS on ventricular function in a canine post-infarction
high-rate pacing model of heart failure. They found that a
greater recovery in ejection fraction was noted in the SCS
(52 ± 5%) group compared with a group treated by beta
blockers ?ACE inhibitors (38 ± 2%) and a control
(31 ± 4%) group. Furthermore, there was a reduction in
serum norepinephrine levels in the SCS-treated dogs,
supporting the hypothesis that SCS reduces sympathetic
tone.
A world-wide study, Defeat-HF, has recently started
enrolling to evaluate the effects of SCS in a systolic heart
failure population. It is a prospective, multicenter, ran-
domized, parallel controlled study expected to enroll up to
70 patients, registered under NCT01112579 at www.
clinicaltrails.gov.
Considerations and perspectives
This review has described several electrical therapies that
are not used broadly in clinical practice as of today.
Adoption of these therapies may be years away given their
efficacy, current means of implementation, and the need for
additional clinical evidence. However, new electrophysio-
logical knowledge and continuous device development
might facilitate the adoption of these therapies in the area
of cardiac disease.
Each of the discussed ‘‘therapies’’ may have its pros and
cons. With respect to the contractility enhancement therapy
involving PESP, the data suggest that chronic application
may not be as arrhythmogenic as feared but also that it does
not result in a large enough positive hemodynamic
response in patients with chronic heart failure. PESP may
have benefit in other conditions where sarcoplasmic retic-
ulum function is closer to normal, however. NES may at
least partly depend upon the local release of nor-epineph-
rine. Regardless of the mechanism, additional data showing
clear benefit in the heart failure population are necessary
for wide-spread adoption. Infarct borderzone stimulation is
a patho-physiologically approach based on reducing stress
and load. Besides that its benefits have to be better sup-
ported by clinical data, the question remains as to whether
long-term stretching of the late-activated region might lead
to decompensation.
Sympathetic stimulation specifically for the heart may
result in controlled modulation of the sympathetic tone of the
left ventricle, but energy costs should be evaluated to ensure
they are not too high. Mechanistically, vagal stimulation
seems to have the greatest potential, because of the strong
association between impaired vagal reflexes and increased
cardiac mortality [60]. However, clinical data are limited.
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